# Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

> **NCT00226473** · PHASE4 · UNKNOWN · sponsor: **Dermatologic Cooperative Oncology Group** · enrollment: 200 (—)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Cisplatin, Vindesine, Dacarbazine (drugs)

## Key facts

- **NCT ID:** NCT00226473
- **Lead sponsor:** Dermatologic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-09
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 200 (—)
- **Last updated:** 2006-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226473, "Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00226473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*